Seeking men and women whose non-small cell lung cancer responded or remained stable to platinum-based chemotherapy and are currently taking pembrolizumab for a study of an investigational drug combination for maintenance therapy.
Participants in this study will be randomly assigned to receive either the investigational drug or placebo (looks like the drug, but contains no medicine). All participants will continue to receive pembrolizumab every 3 weeks.
What we're hoping for
We are studying whether an investigational drug combination is safe and effective compared to treatment with pembrolizumab alone in maintaining control of cancer in people whose non-small cell lung cancer responded to platinum-based chemotherapy.
ClinicalTrials.gov Identifier: NCT04475939